PLASMA PHOSPHOLIPID TRANSFER PROTEIN (PLTP) DEFICIENCY REPRESENTS AN ANTI-ATHEROGENIC STATE AND PLTP INHIBITOR HAS ANTI-ATHEROSCLEROSIS ACTION

摘要

This invention provides methods of decreasing apolipoprotein and of treating atherosclerotic diseases and dyslipidemic diseases by reducing plasma phospholipid transfer protein activity, and methods of identifying chemical compounds for use in such treatments. Figure (1) shows plasma lipoprotein analysis by fast protein liquid chromatography and SDS-PAGE analysis of apoB from ultracentrifugally isolated plasma lipoproteins.